Triple-negative (er, pgr, her-2/neu) breast cancer in indian women

Breast Cancer: Targets and Therapy

Volumn 3, Issue , 2011, Pages 9-19

  Patil, Vinayak W ^a   Singhai, Rajeev ^a   Patil, Amit V ^b   Gurav, Prakash D ^b  

^a SIR J J GROUP OF HOSPITALS   (India)

^b Government Medical College   (India)

Author keywords

Er; Her 2 neu; Hormone receptors; Ki 67; Pgr; Tn breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P53; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RELAPSE; CANCER SURGERY; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIA; LYMPH NODE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICAL SCHOOL; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK FACTOR;

EID: 79952673692     PISSN: None     EISSN: 11791314     Source Type: Journal    
DOI: 10.2147/BCTT.S17094     Document Type: Article

References (36)

1. Ahn SH. Clinical characteristic of breast cancer patients. Arch Surg. 2004;139:27-30.
2. Wood WCMH, Solin LJ, Olopade OI, et al. Malignant Tumors of the Breast. Philadelphia: Lippincott Wiliams & Wilkins; 2005.
3. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature. 2000;406:747-752.
4. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguishes tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001;98:10869-10874.
5. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418-8423.
6. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374.
7. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemo sensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329-2334.
8. Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer. 2007;109:1721-1728.
9. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13:4429-4434.
10. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 2006;24:5652-5657.
11. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006; 295:2492-2502.
12. Kim MJ, Ro JY, Ahn SH, et al. Clinicopathological significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and HER-2/neu-overexpressing phenotypes. Hum Pathol. 2006;37:1217-1226.
13. Keam B, Im SA, Kim HJ, et al. Prognostic impact of clinicopathological parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer. BMC Cancer. 2007;7:203.
14. Lee KH, Im SA, Oh DY, et al. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer. 2007;7:63.
15. Hsu SM, Raine L, Fanger H, et al. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 1981;75:734-738.
16. Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007;8:235-244.
17. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403-410.
18. De la Rochefordiere A, Asselain B, Campana F, et al. Age as prognostic factor in premenopausal breast carcinoma. Lancet. 1993; 341:1039-1043.
19. Nicholson RI, McClelland RA, Relationship between EGF-R, c-erbB-2 protein expression and Ki67 immunostaining in breast cancer and hormone sensitivity. Eur J Cancer. 1993;29A:1018-1023.
20. Xiong Q, Valero V, Kau V, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the MD Anderson Cancer Center experience. Cancer. 2001;92:2523-2528.
21. Callagy GM, Webber MJ, Pharoah PD, et al. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer. 2008;8:153. 22. Daidone MG, Luisi A, Veneroni S, et al. Clinical studies of Bcl-2 and treatment benefit in breast cancer patients. Endocr Relat Cancer. 1999; 6:61-68.
22. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006;7:347-350.
23. Dawson SJ, Makretsov N, Blows FM, et al. BCL2 in breast cancer: a favorable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 2010;103:668-675.
24. Rakha EA, El-Sayed ME, Green AR, et al. Prognostic markers in triplenegative breast cancer. Cancer. 2007;109:25-32.
25. Piccart-Gebhart MJ, Procter M. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005; 353:1659-1672.
26. Foulkes WD, Brunet JS, Stefansson IM, et al. The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-micro vascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res. 2004;64:830-835.
27. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.
28. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007;369:29-36.
29. Turner NC, Reis-Filho JS, Russell AM, et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene. 2007;26:2126-2132.
30. Hiratsuka M, Miura S, Murai H, et al. The prognostic significance of node metastasis in breast cancer. J Japanese. 1994;9:242-245.
31. Veronesi U, et al. Optimal Surgical Treatment of Breast Cancer. The Oncologist. 1996;6:340-346.
32. Auchincloss H, et al. Modified radical mastectomy: Why not? The American Journal of Surgery. 1970;119(5):506-509.
33. Greene FLPD, Fleming ID. AJCC Cancer Staging Manual. New York: Springer; 2002.
34. Nixon AJ, Neuberg D, Hayes DF, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 1994;12:888-894.
35. Hamilton A, Piccart M. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2. Ann Oncol. 2000;11: 647-663.
36. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer. 2004;4:814-819.